Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arena Pharmaceuticals (ARNA)

Arena Pharmaceuticals (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,669,326
  • Shares Outstanding, K 61,074
  • Annual Sales, $ 320 K
  • Annual Income, $ -404,730 K
  • 60-Month Beta 0.49
  • Price/Sales 11,694.04
  • Price/Cash Flow N/A
  • Price/Book 3.79
Trade ARNA with:

Options Overview Details

View History
  • Implied Volatility 53.62%
  • Historical Volatility 35.47%
  • IV Percentile 60%
  • IV Rank 16.91%
  • IV High 119.89% on 10/13/20
  • IV Low 40.14% on 08/06/21
  • Put/Call Vol Ratio 0.19
  • Today's Volume 25
  • Volume Avg (30-Day) 322
  • Put/Call OI Ratio 1.49
  • Today's Open Interest 658
  • Open Int (30-Day) 3,079

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -2.42
  • Number of Estimates 4
  • High Estimate -2.33
  • Low Estimate -2.56
  • Prior Year -1.69
  • Growth Rate Est. (year over year) -43.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.49 +19.12%
on 08/30/21
62.08 -1.21%
on 09/27/21
+8.90 (+16.98%)
since 08/27/21
3-Month
45.50 +34.79%
on 08/19/21
73.91 -17.02%
on 06/28/21
-12.01 (-16.38%)
since 06/25/21
52-Week
45.50 +34.79%
on 08/19/21
90.19 -32.00%
on 11/04/20
-12.36 (-16.77%)
since 09/25/20

Most Recent Stories

More News
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 20 new employees inducement stock options to purchase an aggregate of 33,340...

ARNA : 61.36 (+2.13%)
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M

AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.

JNJ : 163.40 (-0.58%)
ARNA : 61.36 (+2.13%)
TBPH : 7.18 (+2.28%)
AZRX : 3.45 (+2.07%)
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units ("PRSUs"),...

ARNA : 61.36 (+2.13%)
Arena Pharmaceuticals, Inc. (ARNA) Reports Q2 Loss, Lags Revenue Estimates

Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of -8.60% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

ARNA : 61.36 (+2.13%)
Arena Reports Second Quarter Financial Results and Key Program Updates

--- Liquidity position at ~$1.0 billion as of June 30, 2021 to support continued pipeline progress

ARNA : 61.36 (+2.13%)
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers

/PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform sg-4-sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome...

ARNA : 61.36 (+2.13%)
Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2021 financial results and provide a corporate update on Thursday, August 5, 2021, after the close of the U.S. financial markets....

ARNA : 61.36 (+2.13%)
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Aristea Therapeutics, Inc. today announced a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed...

ARNA : 61.36 (+2.13%)
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on July 16, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an...

ARNA : 61.36 (+2.13%)
Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi,...

ARNA : 61.36 (+2.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Key Turning Points

3rd Resistance Point 62.84
2nd Resistance Point 62.07
1st Resistance Point 61.08
Last Price 61.36
1st Support Level 59.32
2nd Support Level 58.55
3rd Support Level 57.56

See More

52-Week High 90.19
Fibonacci 61.8% 73.12
Fibonacci 50% 67.85
Fibonacci 38.2% 62.57
Last Price 61.36
52-Week Low 45.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar